Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to assess the efficacy of stent implantation versus medical therapy on idiopathic intracranial hypertension with venous sinus stenosis.
The SIMPLE is a multicentered, prospective, randomized, open-label, blinded end-point clinical trial. A total of 74 patients with idiopathic intracranial hypertension (IIH) and venous sinus stenosis (VSS) for more than 2 months will be enrolled. Patients fulfilling all of the inclusion criteria and none of the exclusion criteria will be randomized 1:1 into two groups (stenting or medical therapy) after offering informed content.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Stent Implantation | Experimental | The endovascular procedure was performed under general anesthesia. Intravenous heparin was administered during the stent procedure to increase the activated clotting time to > 250 s. An 8F guiding catheter was delivered to the internal jugular vein near the skull base. A 6F Navien intermediate guide catheter was then placed into the distal transverse sinus near the torcula through the 8F guiding catheter. A microguidewire was navigated across the stenosis using a microcatheter, followed by the deployment of a self-expanding stent (eg, Precise or Wallstent) adjusted to the normal sinus venous diameter adjacent to the stenosis. Venography and manometry were performed after the procedure. |
|
| Medical Therapy | Active Comparator | The medical treatment consisted of acetazolamide (0.5-4 g/day) and short-term mannitol (bolus of 0.25-1 g/kg body weight) for a duration of about 1 week or repeated lumbar punctures to reduce intracranial pressure (20 mL each), as well as analgesics for headaches. The initial dosage of acetazolamide was 0.5 g daily in two divided doses, followed by dosage increases of one tablet every week up to a maximum dosage of 4 g/day. The dosage escalation was stopped if the participant had papilledema grade <1 in both eyes, unless the presence of other symptoms such as headache or tinnitus suggested that the dosage escalation should continue. The dosage for the participants who were unable to tolerate the study drug was decreased gradually to a minimum of one half tablet daily. In addition, the weight loss program included a low-calorie diet (≤425 kcal/day) with a target weight loss of approximately 5-10%. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Stent Implantation | Procedure | Aspirin (100 mg) and clopidogrel (75 mg) were administered 3-5 days before endovascular treatment. The endovascular procedure was performed under general anesthesia. Intravenous heparin was administered during the stent procedure to increase the activated clotting time to > 250 s. An 8F guiding catheter was delivered to the internal jugular vein near the skull base. A 6F Navien intermediate guide catheter was then placed into the distal transverse sinus near the torcula through the 8F guiding catheter. A microguidewire was navigated across the stenosis using a microcatheter, followed by the deployment of a self-expanding stent (eg, Precise or Wallstent) adjusted to the normal sinus venous diameter adjacent to the stenosis. Venography and manometry were performed after the procedure. Postoperatively, all patients received dual antiplatelet medications for 3 months and then received a single antiplatelet (either aspirin or clopidogrel). |
| Measure | Description | Time Frame |
|---|---|---|
| Perimetric Mean Deviation (PMD) | The change in perimetric mean deviation (PMD) from baseline to 6 month in the eye with the most severe visual loss at baseline. | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Cerebrospinal Fluid (CSF) Opening Pressure | The change in intracranial pressure measured by lumbar puncture opening pressure from baseline to 6 months. | 6 months |
| Papilledema Grade: Frisén grade(0-5 scores,and higher scores mean worse outcome) |
| Measure | Description | Time Frame |
|---|---|---|
| Functional health status and quality of life:EuroQol five dimensions questionnaire (EQ-5D,0-100,higher scores mean a better outcome) | The change in functional health status and quality of life measured by EuroQol five dimensions questionnaire (EQ-5D) from baseline to 6 months | 6 months |
| Cost-effectiveness analysis (mean costs per patient) |
Inclusion Criteria:
Subject Eligibility Criteria
Ophthalmic Eligibility Criteria:
Exclusion Criteria:
Subject Exclusion Criteria
Ophthalmic Exclusion Criteria:
Current intraocular pressure > 28mmHg or previous intraocular pressure > 30mmHg
Refractive error spherical power greater than -6.0D or +6.0D and astigmatism greater than 3.0D, except for the following cases:
Examination visible or past medical history known to have large optic disc drusen (persistent optic disc edema can present with small optic disc drusen, as low numbers are acceptable for inclusion and to be determined by the investigator to be unrelated to vision loss)
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Xu Tong, MD | Contact | +8617611338800 | dongri0514@sina.com |
| Name | Affiliation | Role |
|---|---|---|
| Dapeng Mo, MD | Beijing Tiantan Hospital | Principal Investigator |
| Zhongrong Miao, MD | Beijing Tiantan Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Beijing Tiantan Hospital | Recruiting | Beijing | Beijing Municipality | 100010 | China |
Not provided
| ID | Term |
|---|---|
| D011559 | Pseudotumor Cerebri |
| ID | Term |
|---|---|
| D019586 | Intracranial Hypertension |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Acetazolamide-based medical therapy | Drug | The medical treatment consisted of acetazolamide (0.5-4 g/day) and short-term mannitol (bolus of 0.25-1 g/kg body weight) for a duration of about 1 week or repeated lumbar punctures to reduce intracranial pressure (20 mL each), as well as analgesics for headaches. The initial dosage of acetazolamide was 0.5 g daily in two divided doses, followed by dosage increases of one tablet every week up to a maximum dosage of 4 g/day. The dosage escalation was stopped if the participant had papilledema grade <1 in both eyes, unless the presence of other symptoms such as headache or tinnitus suggested that the dosage escalation should continue. The dosage for the participants who were unable to tolerate the study drug was decreased gradually to a minimum of one half tablet daily. |
|
| Weight loss | Behavioral | The weight loss program included a low-calorie diet (≤425 kcal/day) with a target weight loss of approximately 5-10%. |
|
The change in papilledema measured by Frisén grade from baseline to 6 months
| 6 months |
| Retinal Nerve Fiber Layer Thickness | The change in thickness of retinal nerve fiber layer measured by optical coherence tomography (OCT) from baseline to 6 months. | 6 months |
| Total Retinal Thickness | The change in thickness of total retina measured by optical coherence tomography (OCT) from baseline to 6 months. | 6 months |
| Visual Acuity: National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25, minimum and maximum values: 0-100 points, higher scores mean a better visual function) | The change in vision measured by National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25) from baseline to 6 months. | 6 months |
| Visual Acuity: 10-item neuro-ophthalmic supplement to the National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25) (minimum and maximum values: 0-100 points, higher scores mean a better visual function) | The change in vision measured by 10-item neuro-ophthalmic supplement to the National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25)from baseline to 6 months. | 6 months |
| Headache: Headache Impact Test-6 (HIT-6, minimum and maximum values: 36-78 points, higher scores mean greater headache severity) | The change in headache measured by Headache Impact Test-6 (HIT-6) questionnaire from baseline to 6 months. | 6 months |
| Pulsatile tinnitus: Tinnitus Handicap Inventory (THI, minimum and maximum values: 0-100 points, higher scores mean more serious tinnitus disability) | The change in pulsatile tinnitus from baseline to 6 months;pulsatile tinnitus was assessed using the Tinnitus Handicap Inventory (THI), which is a self-report measure that can be used in a busy clinical practice to quantify the impact of tinnitus on daily living. | 6 months |
The indicator of cost-effectiveness analysis refers to the mean costs per patient. |
| 6 months |
| Cost-effectiveness analysis (quality-adjusted life years) | The indicator of cost-effectiveness analysis refers to the quality-adjusted life years. | 6 months |
| Cost-effectiveness analysis (the cost saving per extra patient with a good outcome) | The indicator of cost-effectiveness analysis refers to the cost saving per extra patient with a good outcome. | 6 months |
| Cost-effectiveness analysis (the cost saving per additional quality-adjusted life year) | The indicator of cost-effectiveness analysis refers to the cost saving per additional quality-adjusted life year. | 6 months |